|
个人信息Personal Information
教授 博士生导师 硕士生导师
性别：男
毕业院校：山东大学
学历：研究生(博士)毕业
学位：医学博士学位
在职信息：在职
所在单位：药学院
入职时间：2013-02-28
扫描关注
研究领域
1. 药物化学
2. 化学生物学
- . Dual targeting PPARα and NPC1L1 metabolic vulnerabilities blocks tumorigenesis. Cancer letters, 612, 2025.
- . HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. Journal of Medicinal Chemistry, 2025.
- . Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic Chemistry, 153, 2025.
- . Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2024.
- . Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem., 66, 10080, 2023.
- Anil Kumar Marapaka. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. CHINESE CHEMICAL LETTERS, 2550, 2022.
- 通过抑制自噬克服胰腺导管腺癌适应性耐药的组蛋白去乙酰化酶10亚型选择性抑制剂的发现和研究, 2024-08-23-2028-12-31
- 具有抗肝细胞癌耐药、复发和转移优势的组蛋白去乙酰化酶11亚型选择性抑制剂的发现和研究, 2022-09-07-2026-12-31
- HDAC11亚型选择性抑制剂的研发, 2024-09-13-2028-09-30
- EZH2抑制剂Tazemetostat的合成工艺研究, 2022-03-21-2025-12-31
- 基于组蛋白去乙酰化酶HDACs为靶标的抗癌药物研究, 2014-01-01-2016-12-31
- 以HDACs为靶标的抗肿瘤先导化合物ZYJ-34c的成药性研究, 2013-08-15-2016-12-31